Here are the 10-Q quarterly reports from Medpace Holdings, Inc. (MEDP) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MEDP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MEDP filings page.
Medpace Holdings, Inc. reported third-quarter revenue of $716.0 million, up 8.5% from $659.9 million a year earlier. Net income was $137.5 million versus $111.1 million, and diluted earnings per share were $4.84 versus $3.86.
For the nine months ended September 30, 2026, revenue was $2,129.9 million, up 16.9%, and net income was $382.7 million versus $316.0 million. Net cash provided by operating activities was $530.4 million; cash and cash equivalents were $705.3 million as of September 30, 2026. Medpace repurchased 705,616 shares for $294.7 million during the nine months and made no repurchases in the third quarter. Effective October 20, 2026, its board approved a new authorization of up to $1.0 billion after terminating the current authorization.
Separately, August J. Troendle, chief executive officer, president and chairman of the board, adopted a Rule 10b5-1 plan to sell up to 307,959 shares. Susan E. Burwig, executive vice president, operations, adopted one for up to 7,500 shares, and Kevin M. Brady, chief financial officer and treasurer, one for up to 3,400 shares.
Medpace Holdings, Inc. reported strong quarterly results in its Q3 2025 10‑Q. Revenue reached $659.9 million, up 23.7% year over year, driven by growth in Metabolic, Oncology and CNS. Net income was $111.1 million and diluted EPS was $3.86. Operating income rose to $141.8 million as total operating expenses increased with higher reimbursed out‑of‑pocket and personnel costs.
For the first nine months, revenue was $1.82 billion with net income of $316.0 million and diluted EPS of $10.64. Operating cash flow was $520.6 million, while share repurchases totaled $912.9 million year to date, contributing to a decline in cash and equivalents to $285.4 million from $669.4 million at year‑end. The company ended the quarter with $3,000.6 million in backlog and net new awards of $789.6 million in Q3. The effective tax rate was 22.2% in the quarter, reflecting lower FDII benefits.
As of October 17, 2025, common shares outstanding were 28,168,223. The unsecured credit facility remained undrawn with $10.0 million available.